1. Effects of torcetrapid in patients at high risk for coronary events
- Author
-
Barter, Philip J., Caulfield, Mark, Eriksson, Mats, Grundy, Scott M., Kastelein, John J.P., Komajda, Michel, Lopez-Sendon, Jose, Mosca, Lori, Tardif, Jean-Claude, Waters, David D., Shear, Charles L., Revkin, James H., Buhr, Kevin A., Risher, Marian R., Tall, Alan R., and Brewer, Bryan
- Subjects
Torcetrapib (Medication) -- Research ,Torcetrapib (Medication) -- Complications and side effects ,Anticholesteremic agents -- Research ,Anticholesteremic agents -- Complications and side effects ,Heart -- Abnormalities ,Heart -- Risk factors - Abstract
A randomized, double-blind trial was conducted to determine efficacy of torcetrapib, a potent cholesteryl ester transfer protein inhibitor to reduce major cardiovascular events. The trial was terminated prematurely as it increased risk of death and cardiac events in patients receiving torcetrapib.
- Published
- 2007